Literature DB >> 21915624

Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes.

Naoki Yoshimura1, Tokuma Tadami, Takaaki Kawaguchi, Minako Sako, Hiroshi Yoshimoto, Toshihiko Yamaka, Masakazu Takazoe.   

Abstract

BACKGROUND: Hitherto, therapeutic depletion of granulocytes and monocytes by adsorption (GMA) has been associated with significant and insignificant efficacy in patients with ulcerative colitis (UC). Further, the processed blood volume in one GMA session has been fixed at 30 mL/min × 60 min, regardless of patients' body weight (BW). We were interested to see the efficacy and safety of GMA when administered in relation to patients' BW.
METHODS: Sixty patients were randomly assigned to the routine GMA (n = 30) and to GMA adjusted to patients' BW, 60 mL/kg (n = 30). GMA was done with the Adacolumn, up to 10 sessions over 10 weeks. At entry and 1 week post last GMA, patients were clinically and endoscopically evaluated. Remission was defined as clinical activity index (CAI) ≤4, whereas mucosal remission was defined as endoscopic index (EI) ≤3.
RESULTS: In the BW group, the processed volume/session was 3,260 ± 581 versus 1,800 mL in the routine group (P < 0.001). In the BW group, 25 of 30 patients (83.3%) achieved remission versus 19 of 30 patients (63.3%) in the routine group. The average CAI in the BW group fell from 9.6 ± 2.6 to 2.3 ± 2.1 versus from 9.1 ± 2.4 to 4.0 ± 2.1 (P < 0.05) in the routine group. Similarly, the EI in the BW group fell from 9.4 ± 1.3 to 2.1 ± 2.1 versus from 9.2 ± 1.8 to 4.5 ± 2.3 (P < 0.01).
CONCLUSIONS: GMA adjusted to patients' BW and at a vastly greater processed volume produces significantly higher efficacy as compared with the routine GMA protocol. Further, in this study, up to twofold higher processed volume caused no safety concern.

Entities:  

Mesh:

Year:  2011        PMID: 21915624     DOI: 10.1007/s00535-011-0464-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  36 in total

1.  Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.

Authors:  V Muratov; J Lundahl; A K Ulfgren; K Elvin; I Fehrman; N Ahlborg; A Ost; N Hittel; A Saniabadi; R Löfberg
Journal:  Int J Colorectal Dis       Date:  2006-03-15       Impact factor: 2.571

2.  A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis.

Authors:  Bruce E Sands; William J Sandborn; Brian Feagan; Robert Löfberg; Toshifumi Hibi; Tao Wang; Lisa-Marie Gustofson; Cindy J Wong; Margaret K Vandervoort; Stephen Hanauer
Journal:  Gastroenterology       Date:  2008-04-25       Impact factor: 22.682

3.  The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF.

Authors:  Kai-Uwe Belge; Farshid Dayyani; Alexia Horelt; Maciej Siedlar; Marion Frankenberger; Bernhard Frankenberger; Terje Espevik; Löms Ziegler-Heitbrock
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

4.  Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study.

Authors:  T Shimoyama; K Sawada; N Hiwatashi; T Sawada; K Matsueda; A Munakata; H Asakura; T Tanaka; R Kasukawa; K Kimura; Y Suzuki; Y Nagamachi; T Muto; H Nagawa; B Iizuka ; S Baba; M Nasu; T Kataoka; N Kashiwagi; A R Saniabadi
Journal:  J Clin Apher       Date:  2001       Impact factor: 2.821

5.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

Authors:  J A Tibble; G Sigthorsson; S Bridger; M K Fagerhol; I Bjarnason
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

6.  A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis.

Authors:  Yasuo Suzuki; Naoki Yoshimura; Katsuyuki Fukuda; Koji Shirai; Yasushi Saito; Abbi R Saniabadi
Journal:  Dig Dis Sci       Date:  2006-09-27       Impact factor: 3.199

7.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

8.  Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan.

Authors:  T Hibi; Y Sameshima; Y Sekiguchi; Y Hisatome; F Maruyama; K Moriwaki; C Shima; A R Saniabadi; T Matsumoto
Journal:  Dig Liver Dis       Date:  2009-02-10       Impact factor: 4.088

9.  Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse.

Authors:  Laurence Maiden; Ken Takeuchi; Rosie Baur; Ingi Bjarnason; John O'Donohue; Ian Forgacs; Guy Chung-Faye; Jeremy Sanderson; Ingvar Bjarnason
Journal:  Inflamm Bowel Dis       Date:  2008-10       Impact factor: 5.325

10.  Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study.

Authors:  Yasuo Suzuki; Naoki Yoshimura; Abby R Saniabadi; Yasushi Saito
Journal:  Dig Dis Sci       Date:  2004-04       Impact factor: 3.199

View more
  4 in total

Review 1.  Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.

Authors:  Abbi R Saniabadi; Tomotaka Tanaka; Toshihide Ohmori; Koji Sawada; Takayuki Yamamoto; Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

2.  Uveitis and T cell lymphoma: a rare but notable relationship.

Authors:  Yamin Lai; Meifen Zhang; Li Wang; Aiming Yang; Jingnan Li; Xiao Zhang; Xiang Zhou; Tao Hong; Jiaming Qian; Dingrong Zhong
Journal:  Med Oncol       Date:  2014-06-25       Impact factor: 3.064

Review 3.  Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future.

Authors:  Xiu-Li Chen; Jing-Wei Mao; Ying-De Wang
Journal:  World J Gastrointest Pathophysiol       Date:  2020-05-12

4.  Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA.

Authors:  Yoko Yokoyama; Mikio Kawai; Ken Fukunaga; Koji Kamikozuru; Kazuko Nagase; Koji Nogami; Tomoaki Kono; Yoshio Ohda; Masaki Iimuro; Nobuyuki Hida; Shiro Nakamura; Hiroto Miwa; Takayuki Matsumoto
Journal:  BMC Gastroenterol       Date:  2013-02-12       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.